Imperial College London
Portrait Picture

Professor Marc-Emmanuel Dumas

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Chair in Systems Medicine
 
 
 
//

Contact

 

+44 (0)20 7594 1820m.dumas Website

 
 
//

Assistant

 

Mrs Patricia Murphy +44 (0)20 7594 1603

 
//

Location

 

E315BBurlington DanesHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Fromentin:2022:10.1038/s41591-022-01688-4,
author = {Fromentin, S and Forslund, SK and Chechi, K and Aron-Wisnewsky, J and Chakaroun, R and Nielsen, T and Tremaroli, V and Ji, B and Prifti, E and Myridakis, A and Chilloux, J and Andrikopoulos, P and Fan, Y and Olanipekun, MT and Alves, R and Adiouch, S and Bar, N and Talmor-Barkan, Y and Belda, E and Caesar, R and Coelho, LP and Falony, G and Fellahi, S and Galan, P and Galleron, N and Helft, G and Hoyles, L and Isnard, R and Le, Chatelier E and Julienne, H and Olsson, L and Pedersen, HK and Pons, N and Quinquis, B and Rouault, C and Roume, H and Salem, J-E and Schmidt, TSB and Vieira-Silva, S and Li, P and Zimmermann-Kogadeeva, M and Lewinter, C and Sondertoft, NB and Hansen, TH and Gauguier, D and Gotze, JP and Kober, L and Kornowski, R and Vestergaard, H and Hansen, T and Zucker, J-D and Hercberg, S and Letunic, I and Backhed, F and Oppert, J-M and Nielsen, J and Raes, J and Bork, P and Stumvoll, M and Segal, E and Clement, K and Dumas, M-E and Ehrlich, SD and Pedersen, O},
doi = {10.1038/s41591-022-01688-4},
journal = {Nature Medicine},
pages = {303--+},
title = {Microbiome and metabolome features of the cardiometabolic disease spectrum},
url = {http://dx.doi.org/10.1038/s41591-022-01688-4},
volume = {28},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Previous microbiome and metabolome analyses exploring non-communicable diseases have paid scant attention to major confounders of study outcomes, such as common, pre-morbid and co-morbid conditions, or polypharmacy. Here, in the context of ischemic heart disease (IHD), we used a study design that recapitulates disease initiation, escalation and response to treatment over time, mirroring a longitudinal study that would otherwise be difficult to perform given the protracted nature of IHD pathogenesis. We recruited 1,241 middle-aged Europeans, including healthy individuals, individuals with dysmetabolic morbidities (obesity and type 2 diabetes) but lacking overt IHD diagnosis and individuals with IHD at three distinct clinical stages—acute coronary syndrome, chronic IHD and IHD with heart failure—and characterized their phenome, gut metagenome and serum and urine metabolome. We found that about 75% of microbiome and metabolome features that distinguish individuals with IHD from healthy individuals after adjustment for effects of medication and lifestyle are present in individuals exhibiting dysmetabolism, suggesting that major alterations of the gut microbiome and metabolome might begin long before clinical onset of IHD. We further categorized microbiome and metabolome signatures related to prodromal dysmetabolism, specific to IHD in general or to each of its three subtypes or related to escalation or de-escalation of IHD. Discriminant analysis based on specific IHD microbiome and metabolome features could better differentiate individuals with IHD from healthy individuals or metabolically matched individuals as compared to the conventional risk markers, pointing to a pathophysiological relevance of these features.
AU  - Fromentin,S
AU  - Forslund,SK
AU  - Chechi,K
AU  - Aron-Wisnewsky,J
AU  - Chakaroun,R
AU  - Nielsen,T
AU  - Tremaroli,V
AU  - Ji,B
AU  - Prifti,E
AU  - Myridakis,A
AU  - Chilloux,J
AU  - Andrikopoulos,P
AU  - Fan,Y
AU  - Olanipekun,MT
AU  - Alves,R
AU  - Adiouch,S
AU  - Bar,N
AU  - Talmor-Barkan,Y
AU  - Belda,E
AU  - Caesar,R
AU  - Coelho,LP
AU  - Falony,G
AU  - Fellahi,S
AU  - Galan,P
AU  - Galleron,N
AU  - Helft,G
AU  - Hoyles,L
AU  - Isnard,R
AU  - Le,Chatelier E
AU  - Julienne,H
AU  - Olsson,L
AU  - Pedersen,HK
AU  - Pons,N
AU  - Quinquis,B
AU  - Rouault,C
AU  - Roume,H
AU  - Salem,J-E
AU  - Schmidt,TSB
AU  - Vieira-Silva,S
AU  - Li,P
AU  - Zimmermann-Kogadeeva,M
AU  - Lewinter,C
AU  - Sondertoft,NB
AU  - Hansen,TH
AU  - Gauguier,D
AU  - Gotze,JP
AU  - Kober,L
AU  - Kornowski,R
AU  - Vestergaard,H
AU  - Hansen,T
AU  - Zucker,J-D
AU  - Hercberg,S
AU  - Letunic,I
AU  - Backhed,F
AU  - Oppert,J-M
AU  - Nielsen,J
AU  - Raes,J
AU  - Bork,P
AU  - Stumvoll,M
AU  - Segal,E
AU  - Clement,K
AU  - Dumas,M-E
AU  - Ehrlich,SD
AU  - Pedersen,O
DO  - 10.1038/s41591-022-01688-4
EP  - 303
PY  - 2022///
SN  - 1078-8956
SP  - 303
TI  - Microbiome and metabolome features of the cardiometabolic disease spectrum
T2  - Nature Medicine
UR  - http://dx.doi.org/10.1038/s41591-022-01688-4
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000757243200006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.nature.com/articles/s41591-022-01688-4
UR  - http://hdl.handle.net/10044/1/96664
VL  - 28
ER  -
Download